First human trial launches for experimental PSTB100 drug

NCT ID NCT07702279

Not yet recruiting Knowledge-focused Sponsor: Prospect Therapeutics (Nanjing) Limited Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This first-in-human study tests the safety and tolerability of PSTB100 tablets in healthy adults aged 18 to 55. Participants receive either a single or multiple doses of the drug or a placebo. Researchers measure how the body absorbs, processes, and eliminates PSTB100 to guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSTB100 tablets
What this could lead to: If successful, this early study could pave the way for future trials exploring PSTB100 as a potential treatment.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing in healthy people, not on treating any disease. It may not lead to any therapeutic benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT SUBJECTS

Contacts and locations

Show contact details

Locations

Nucleus Network Pty Ltd

Brisbane, Queensland, 4006, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.